~~<i id='0E612CCFBD'><strike id='0E612CCFBD'><tt id='0E612CCFBD'><pre id='0E612CCFBD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：fashion 2025-09-29 12:09:05 - browse：314

Elite athletes really are different from you and me. Or, at least their gut microbes are.

Scientists who analyzed stool samples of 15 runners a week before and after they competed in the 2015 Boston Marathon found unusually high levels of one particular microbe compared to 10 non-athletes. Levels of the microbe in question, Veillonella, spiked after an intense workout and bloomed even more after the marathon.

That was a lightbulb moment for the scientists because the bacterium is known for breaking down and eating lactate, a metabolite even ordinary runners equate with fatigue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Sen. Paul opposes bill to ban Chinese biotechs

entertainment

Wikipedia

hotspot

explore

focus

LISELOTTESABROE/AFP/GettyImagesApillbeingdevelopedbyDanishdrugmakerNovoNordiskmayleadtogreaterweight

WSS

How to bring more disabled researchers into academia

Amylyx ALS drug failure raises questions and concerns

The future of health care in the House

NEJM study link tiny plastics in blood vessels to heart problems

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

A deep dive into Applied Therapeutics’ data, and questions on Cassava

explore

hotspot

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What to expect at HLTH 2023, the health care industry conference

Heart attack and stroke risk calculators need revising

Sana to lay off nearly a third of staff, de

Dobbs anniversary: the lost opportunity of abortion as health care

Bill would stop addiction treatment from triggering child abuse inquiry

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA rejects Alnylam's heart disease treatment over insufficient data

Heart attack and stroke risk calculators need revising

CDC marks new Covid

Wikipedia

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Bristol 'take

NEJM study link tiny plastics in blood vessels to heart problems

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

A Q&A with the global head of Boehringer Ingelheim's innovation unit

CDC marks new Covid

hotspot

explore

focus

focus